Fenofibrate inhibits atrial metabolic remodelling in atrial fibrillation through PPAR-α/sirtuin 1/PGC-1α pathway

British Journal of Pharmacology

Volumn 173, Issue 6, 2016, Pages 1095-1109

  Zhao, Jing ^c   Liu, Guang Zhong ^a   Hou, Ting Ting ^a   Yuan, Yue ^a   Hang, Peng Zhou ^b   Zhao, Jing Jing ^a   Sun, Li ^a   Zhao, Guan Qi ^a   Dong, Jing Mei ^a   Wang, Xiao Bing ^a   Shi, Hang ^a   Liu, Yong Wu ^d   Zhou, Jing Hua ^d   Dong, Zeng Xiang ^c   Liu, Yang ^a   Zhan, Cheng Chuang ^a   Li, Yue ^a,c   Li, Wei Min ^a,c  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

^d HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE NUCLEOTIDE; FAT DROPLET; FENOFIBRATE; GLYCOGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; SIRTUIN 1; 6-CHLORO-2,3,4,9-TETRAHYDRO-1H-CARBAZOLE-1-CARBOXAMIDE; CARBAZOLE DERIVATIVE; GW 6471; OXAZOLE DERIVATIVE; TYROSINE;

ADULT; ANIMAL EXPERIMENT; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENERGY METABOLISM; HEART ATRIUM REMODELING; HUMAN; HUMAN TISSUE; MALE; METABOLITE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; SIGNAL TRANSDUCTION; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; DRUG EFFECTS; HEART ATRIUM; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; ATRIAL FIBRILLATION; ATRIAL REMODELING; CARBAZOLES; CELL LINE; FENOFIBRATE; HEART ATRIA; HUMANS; MALE; MIDDLE AGED; OXAZOLES; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA; PPAR ALPHA; RABBITS; SIRTUIN 1; TYROSINE;

EID: 84960145831     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13438     Document Type: Article

References (61)

1. Alexander SPH, Cidlowski JA, Kelly E, Marrion N, Peters JA, Benson HE, et al., (2015a). The Concise Guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors. Br J Pharmacol 172: 5956-5978.
2. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al., (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024-6109.
3. Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, et al., (2015c). The Concise Guide to PHARMACOLOGY 2015/16: Transporters. Br J Pharmacol 172: 6110-6202.
4. Asai T, Okumura K, Takahashi R, Matsui H, Numaguchi Y, Murakami H, et al., (2006). Combined therapy with PPARalpha agonist and L-carnitine rescues lipotoxic cardiomyopathy due to systemic carnitine deficiency. Cardiovasc Res 70: 566-577.
5. Ausma J, Coumans WA, Duimel H, Van der Vusse GJ, Allessie MA, Borgers M, (2000). Atrial high energy phosphate content and mitochondrial enzyme activity during chronic atrial fibrillation. Cardiovasc Res 47: 788-796.
6. Barbieri M, Di Filippo C, Esposito A, Marfella R, Rizzo MR, D'Amico M, et al., (2012). Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-gamma-knockout (CM-PGKO) mice. PLoS One 7: e35999.
7. Barth AS, Merk S, Arnoldi E, Zwermann L, Kloos P, Gebauer M, et al., (2005). Reprogramming of the human atrial transcriptome in permanent atrial fibrillation: expression of a ventricular-like genomic signature. Circ Res 96: 1022-1029.
8. Bhullar KS, Hubbard BP, (2015). Lifespan and healthspan extension by resveratrol. Biochim Biophys Acta 1852: 1209-1218.
9. Bonzo JA, Brocker C, Jiang C, Wang RH, Deng CX, Gonzalez FJ, (2014). Hepatic sirtuin 1 is dispensable for fibrate-induced peroxisome proliferator-activated receptor-alpha function in vivo. Am J Physiol Endocrinol Metab 306: E824-E837.
10. Brundel BJ, Shiroshita-Takeshita A, Qi X, Yeh YH, Chartier D, van Gelder IC, et al., (2006). Induction of heat shock response protects the heart against atrial fibrillation. Circ Res 99: 1394-1402.
11. Casaclang-Verzosa G, Gersh BJ, Tsang TS, (2008). Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol 51: 1-11.
12. Cha YM, Dzeja PP, Shen WK, Jahangir A, Hart CY, Terzic A, et al., (2003). Failing atrial myocardium: energetic deficits accompany structural remodeling and electrical instability. Am J Physiol Heart Circ Physiol 284: H1313-H1320.
13. Chang HC, Guarente L, (2014). SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metabol: TEM 25: 138-145.
14. Chilukoti RK, Giese A, Malenke W, Homuth G, Bukowska A, Goette A, et al., (2015). Atrial fibrillation and rapid acute pacing regulate adipocyte/adipositas-related gene expression in the atria. Int J Cardiol 187: 604-613.
15. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA, et al., (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461-3471.
16. De Angelis A, Piegari E, Cappetta D, Russo R, Esposito G, Ciuffreda LP, et al., (2015). SIRT1 activation rescues doxorubicin-induced loss of functional competence of human cardiac progenitor cells. Int J Cardiol 189: 30-44.
17. Guarente L, (2006). Sirtuins as potential targets for metabolic syndrome. Nature 444: 868-874.
18. Harada M, Tadevosyan A, Qi X, Xiao J, Liu T, Voigt N, et al., (2015). Atrial Fibrillation Activates AMP-Dependent Protein Kinase and its Regulation of Cellular Calcium Handling: Potential Role in Metabolic Adaptation and Prevention of Progression. J Am Coll Cardiol 66: 47-58.
19. Heijman J, Voigt N, Nattel S, Dobrev D, (2014). Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res 114: 1483-1499.
20. Hennuyer N, Poulain P, Madsen L, Berge RK, Houdebine LM, Branellec D, et al., (1999). Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response. Circulation 99: 2445-2451.
21. Hong YA, Lim JH, Kim MY, Kim TW, Kim Y, Yang KS, et al., (2014). Fenofibrate improves renal lipotoxicity through activation of AMPK-PGC-1alpha in db/db mice. PLoS One 9: e96147.
22. Huang XS, Zhao SP, Bai L, Hu M, Zhao W, Zhang Q, (2009). Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-alpha. Br J Pharmacol 158: 706-712.
23. Kashiwaya Y, Sato K, Tsuchiya N, Thomas S, Fell DA, Veech RL, et al., (1994). Control of glucose utilization in working perfused rat heart. J Biol Chem 269: 25502-25514.
24. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
25. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al., (2006). Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109-1122.
26. Lam VH, Zhang L, Huqi A, Fukushima A, Tanner BA, Onay-Besikci A, et al., (2015). Activating PPARalpha prevents post-ischemic contractile dysfunction in hypertrophied neonatal hearts. Circ Res 117: 41-51.
27. Lenski M, Schleider G, Kohlhaas M, Adrian L, Adam O, Tian Q, et al., (2015). Arrhythmia causes lipid accumulation and reduced glucose uptake. Basic Res Cardiol 110: 40. doi: 10.1007/s00395-015-0497-2.
28. Li Y, Li WM, Gong YT, Li BX, Liu W, Han W, et al., (2007). The effects of cilazapril and valsartan on the mRNA and protein expressions of atrial calpains and atrial structural remodeling in atrial fibrillation dogs. Basic Res Cardiol 102: 245-256.
29. Li Y, Shi J, Yang BF, Liu L, Han CL, Li WM, et al., (2012). Ketamine-induced ventricular structural, sympathetic and electrophysiological remodelling: pathological consequences and protective effects of metoprolol. Br J Pharmacol 165: 1748-1756.
30. Liang F, Wang F, Zhang S, Gardner DG, (2003). Peroxisome proliferator activated receptor (PPAR)alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes. Endocrinology 144: 4187-4194.
31. Liu Y, Geng J, Liu Y, Li Y, Shen J, Xiao X, et al., (2013). beta3-adrenoceptor mediates metabolic protein remodeling in a rabbit model of tachypacing-induced atrial fibrillation. Cell Physiol Biochem 32: 1631-1642.
32. Madrazo JA, Kelly DP, (2008). The PPAR trio: regulators of myocardial energy metabolism in health and disease. J Mol Cell Cardiol 44: 968-975.
33. Mayr M, Yusuf S, Weir G, Chung YL, Mayr U, Yin X, et al., (2008). Combined metabolomic and proteomic analysis of human atrial fibrillation. J Am Coll Cardiol 51: 585-594.
34. McGrath JC, Lilley E, (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189-3193.
35. Meng RS, Pei ZH, Yin R, Zhang CX, Chen BL, Zhang Y, et al., (2009). Adenosine monophosphate-activated protein kinase inhibits cardiac hypertrophy through reactivating peroxisome proliferator-activated receptor-alpha signaling pathway. Eur J Pharmacol 620: 63-70.
36. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, et al., (2001). Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 104: 174-180.
37. Okada M, Sano F, Ikeda I, Sugimoto J, Takagi S, Sakai H, et al., (2009). Fenofibrate-induced muscular toxicity is associated with a metabolic shift limited to type-1 muscles in rats. Toxicol Pathol 37: 517-520.
38. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al., NC-IUPHAR(2014). The IUPHAR/BPS guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucleic Acids Res 42: D1098-D1106.
39. Planavila A, Iglesias R, Giralt M, Villarroya F, (2011). Sirt1 acts in association with PPARalpha to protect the heart from hypertrophy, metabolic dysregulation, and inflammation. Cardiovasc Res 90: 276-284.
40. Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X, (2009). Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 9: 327-338.
41. Saito T, Yamada E, Okada S, Shimoda Y, Tagaya Y, Hashimoto K, et al., (2014). Nucleobindin-2 is a positive regulator for insulin-stimulated glucose transporter 4 translocation in fenofibrate treated E11 podocytes. Endocr J 61: 933-939.
42. Sasaki T, Maier B, Koclega KD, Chruszcz M, Gluba W, Stukenberg PT, et al., (2008). Phosphorylation regulates SIRT1 function. PLoS One 3: e4020.
43. Seiler PU, Stypmann J, Breithardt G, Schulze-Bahr E, (2004). Real-time RT-PCR for gene expression profiling in blood of heart failure patients-a pilot study: gene expression in blood of heart failure patients. Basic Res Cardiol 99: 230-238.
44. Sellevold OF, Jynge P, Aarstad K, (1986). High performance liquid chromatography: a rapid isocratic method for determination of creatine compounds and adenine nucleotides in myocardial tissue. J Mol Cell Cardiol 18: 517-527.
45. Seo YS, Kim JH, Jo NY, Choi KM, Baik SH, Park JJ, et al., (2008). PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. J Gastroenterol Hepatol 23: 102-109.
46. Seppet E, Eimre M, Peet N, Paju K, Orlova E, Ress M, et al., (2005). Compartmentation of energy metabolism in atrial myocardium of patients undergoing cardiac surgery. Mol Cell Biochem 270: 49-61.
47. Sharma NS, Nagrath D, Yarmush ML, (2011). Metabolic profiling based quantitative evaluation of hepatocellular metabolism in presence of adipocyte derived extracellular matrix. PLoS One 6: e20137.
48. Sin TK, Yung BY, Siu PM, (2015). Modulation of SIRT1-Foxo1 signaling axis by resveratrol: implications in skeletal muscle aging and insulin resistance. Cell Physiol Biochem 35: 541-552.
49. Sugga GS, Khan MU, Khanam R, (2012). Protective role of fibrates in cardiac ischemia/reperfusion. J Adv Pharm Tech Res 3: 188-192.
50. Tanno M, Kuno A, Yano T, Miura T, Hisahara S, Ishikawa S, et al., (2010). Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J Biol Chem 285: 8375-8382.
51. Tanno M, Sakamoto J, Miura T, Shimamoto K, Horio Y, (2007). Nucleocytoplasmic shuttling of the NAD + -dependent histone deacetylase SIRT1. J Biol Chem 282: 6823-6832.
52. Tsuboi M, Hisatome I, Morisaki T, Tanaka M, Tomikura Y, Takeda S, et al., (2001). Mitochondrial DNA deletion associated with the reduction of adenine nucleotides in human atrium and atrial fibrillation. Eur J Clin Invest 31: 489-496.
53. Tu T, Zhou S, Liu Z, Li X, Liu Q, (2014). Quantitative proteomics of changes in energy metabolism-related proteins in atrial tissue from valvular disease patients with permanent atrial fibrillation. Circ J 78: 993-1001.
54. van Bragt KA, Nasrallah HM, Kuiper M, Luiken JJ, Schotten U, Verheule S, (2014). Atrial supply-demand balance in healthy adult pigs: coronary blood flow, oxygen extraction, and lactate production during acute atrial fibrillation. Cardiovasc Res 101: 9-19.
55. Wang W, Lin Q, Lin R, Zhang J, Ren F, Zhang J, et al., (2013). PPARalpha agonist fenofibrate attenuates TNF-alpha-induced CD40 expression in 3T3-L1 adipocytes via the SIRT1-dependent signaling pathway. Exp Cell Res 319: 1523-1533.
56. Wang WR, Liu EQ, Zhang JY, Li YX, Yang XF, He YH, et al., (2015). Activation of PPAR alpha by fenofibrate inhibits apoptosis in vascular adventitial fibroblasts partly through SIRT1-mediated deacetylation of FoxO1. Exp Cell Res 338: 54-63. doi: 10.1016/j.yexcr.2015.07.027.
57. Xu QY, Liu YH, Zhang Q, Ma B, Yang ZD, Liu L, et al., (2014). Metabolomic analysis of simvastatin and fenofibrate intervention in high-lipid diet-induced hyperlipidemia rats. Acta Pharmacol Sin 35: 1265-1273.
58. Yang Z, Shen W, Rottman JN, Wikswo JP, Murray KT, (2005). Rapid stimulation causes electrical remodeling in cultured atrial myocytes. J Mol Cell Cardiol 38: 299-308.
59. Zarzuelo MJ, Lopez-Sepulveda R, Sanchez M, Romero M, Gomez-Guzman M, Ungvary Z, et al., (2013). SIRT1 inhibits NADPH oxidase activation and protects endothelial function in the rat aorta: implications for vascular aging. Biochem Pharmacol 85: 1288-1296.
60. Zhao J, Li J, Li W, Li Y, Shan H, Gong Y, et al., (2010). Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Br J Pharmacol 159: 1584-1594.
61. Zhao T, Deng YP, Ni M, Chen JK, Li ZP, Li DJ, et al., (2014). Fenofibrate improves the impaired endothelial progenitor cell function through inhibiting eNOS uncoupling in diabetic mice. Br J Pharmacol 172: 5704-5728. doi: 10.1111/bph.13054.